Keyword: Claire McCaskill
Five more lawmakers are piling on Allergan for the company's controversial tribal licensing deal.
Confronted with an investigation into its Vivitrol marketing, Alkermes contends it’s just trying to help the U.S. get control of the opioid crisis.
Sen. Claire McCaskill is moving to shut down the "brazen loophole" exposed in Allergan's tribal licensing deal.
Sen. Claire McCaskill is wondering whether Allergan's recent tribal licensing agreement is in agreement with PhRMA's mission.
Insys Therapeutics is the focus of a new congressional report detailing some former employees' sales techniques for powerful painkiller Subsys.
Democrats rolled out their new economic agenda Monday, calling it a “Better Deal.” For consumers, maybe. For the pharma industry, not so much.
Ohio’s attorney general is going after drugmakers for alleged “fraudulent marketing practices” on opioid painkillers.
The painkiller Ofirmev doubled in price after Mallinckrodt bought it—and it's the latest investigative target of Sen. Claire McCaskill. But this probe isn’t so cut-and-dried.
A top Senate Democrat is throwing the weight of her office behind efforts to dig into opioid marketing practices.
The power of a Hillary Clinton tweet showed again Wednesday, when the presidential candidate spoke on drug price, raising fears of government action. Biotech stocks, pharma stocks--even U.K. drugmakers suffered.